Outcomes remain poor for children with rhabdomyosarcoma (RMS) and Ewing sarcoma (EWS), two aggressive cancers that are very difficult to cure once they come back. Current treatments, like irinotecan, can cause significant side effects. A related drug, exatecan, is more powerful but has not been widely used because it can be too toxic.